Minerva Urology and Nephrology最新文献

{"title":"Is it simpler with single-port?. A comparative analysis of single-port robot-assisted simple and radical nephrectomy in a tertiary referral center.","authors":"Hakan B Haberal, Valerio Santarelli, Fabio M Valenzi, Muhannad Aljoulani, Alexandru Turcan, Flavia Tamborino, Filippo Carletti, Luca Lambertini, Giulio Avesani, Matteo Pacini, Ruben Calvo Sauer, Juan R Torres-Anguiano, Simone Crivellaro","doi":"10.23736/S2724-6051.25.06476-6","DOIUrl":"https://doi.org/10.23736/S2724-6051.25.06476-6","url":null,"abstract":"<p><strong>Background: </strong>Simple nephrectomy (SN), a procedure performed for benign kidney conditions, can be more challenging and complicated than radical nephrectomy (RN). With the widespread adoption of minimally invasive surgery, robotic platforms have also been introduced for SN. In this study, we aim to compare perioperative outcomes and complications between single-port (SP) robotic-assisted (RA) SN and RN in a tertiary referral center.</p><p><strong>Methods: </strong>Data from 63 consecutive patients who underwent SP-RASN and SP-RARN between December 2018 and December 2024 at a single center, performed by a single surgeon, were evaluated. We compared baseline patient characteristics, intraoperative and postoperative outcomes.</p><p><strong>Results: </strong>A total of 33 SP-RARN and 30 SP-RASN were included. There were no differences between the two groups in terms of operation time and estimated blood loss (P=0.741, P=0.587, respectively). None of the patients in the SP-RASN group required conversion to open surgery, and no intraoperative complications were observed. In the SP-RASN group, the median length of hospital stay (LOS) was 0.5 (0-1.25) days, and the same-day discharge (SDD) rate was 50%. The numbers of patients with Clavien grade 1 and grade 2 complications for SP-RASN was 3 (10%) and 4 (13.3%), respectively. There was a 0% incidence of major postoperative complications (≥Clavien-Dindo grade 3). LOS, SDD, postoperative complications and readmission rates were similar between groups (P=0.120, P=0.064, P=0.854, P=0.498, respectively).</p><p><strong>Conclusions: </strong>SP-RASN is a feasible option for the management of benign renal conditions/diseases, offering a low postoperative complication rate and the possibility of SDD.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145071166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using cumulative summation analysis for the learning curve of robotic docking time in radical prostatectomy with the HUGO RAS System.","authors":"Pierluigi P Russo, Mariachiara M Sighinolfi, Sara S Mastrovito, Antonio A Cretì, Giovanni G Panico, Filippo F Marino, Simona S Presutti, Eros E Scarciglia, Francesco P Bizzarri, Domenico D Nigro, Carlo C Gandi, Mauro M Ragonese, Filippo F Gavi, Savio D Pandolfo, Angelo A Totaro, Emilio E Sacco, Nazario N Foschi, Bernardo B Rocco","doi":"10.23736/S2724-6051.25.06389-X","DOIUrl":"https://doi.org/10.23736/S2724-6051.25.06389-X","url":null,"abstract":"<p><p>Minimally invasive surgery like robotic surgery is known to yield better outcomes in terms of blood loss, blood transfusion, and length of stay, and robot-assisted radical prostatectomy provides a clear example compared to open surgery. It is still constrained by issues related to platform availability and cost-effectiveness. Introducing new robotic platforms, such as the HUGO^™ Robot-Assisted Surgery (RAS) System, could lead to longer operating times caused by the surgeon's learning curve, system configuration, adjustment of robotic devices, and robotic docking. Several studies have assessed the influence of resident physicians on outcomes in urological surgeries. Our main objective was to evaluate the learning curve of the docking time for 195 radical prostatectomies performed in our hospital. The results of our research indicate that the setup and docking process with the HUGO RAS system can be accomplished with ease, and the learning curve for robotic docking is consistent with the available data for other robotic platforms. Our training facilitated a rapid docking process and seamless completion of the surgery.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uro-vaxom (OM-89) for chronic UTI prevention: an updated meta-analysis, meta-regression and trial sequential analysis of recent clinical evidence.","authors":"Breno C Porto, Artur S Almeida, Bruno D Terada, Felipe G Gonçalves, Carlo C Passerotti, Rodrigo A Sardenberg, Jose P Otoch, Jose A DA Cruz","doi":"10.23736/S2724-6051.25.06366-9","DOIUrl":"https://doi.org/10.23736/S2724-6051.25.06366-9","url":null,"abstract":"<p><strong>Introduction: </strong>Recurrent urinary tract infections (UTIs) are a common health issue that affects patients' quality of life and healthcare systems. To reduce antibiotic use, non-antimicrobial treatments, such as Uro-Vaxom (OM-89), have been proposed to prevent UTI recurrence by enhancing immune response. Still, despite being available for many years, the evidence for its effectiveness remains unclear. This updated systematic review and meta-analysis aims to evaluate the efficacy of OM-89 in reducing UTI recurrence, increasing sample size compared to previous reviews.</p><p><strong>Evidence acquisition: </strong>A systematic review was conducted using MEDLINE, Embase, Scopus, Cochrane, Web of Science, and Google Scholar, following the PRISMA guidelines. We included randomized controlled trials (RCTs) comparing OM-89 with placebo in adult patients with a history of recurrent UTIs. Study selection and data extraction were performed by multiple reviewers, and a random-effects model was used for data pooling. Our primary outcome was the recurrence rate of symptomatic UTIs, while secondary endpoints included the rate of positive urine cultures at 3 and 6 months post-intervention. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool, and statistical analysis was conducted using RStudio software. Additionally, we performed a meta-regression incorporating all included studies for primary endpoint.</p><p><strong>Evidence synthesis: </strong>We retrieved eight RCTs, comprising 674 patients in the OM-89 group and 677 patients in the placebo group. Our analysis showed a lower rate of symptomatic UTIs in the intervention group (OR 0.48; 95% CI 0.23-0.97; P<0.01; I²=81%). Similarly, bacteriuria at both 3 and 6 months after treatment was less frequent in patients treated with OM-89 compared to placebo (OR 0.23; 95% CI 0.10-0.53; P=0.03) and (OR 0.45; 95% CI 0.23-0.89; P=0.02), respectively. Meta-regression revealed a trend suggesting that the effectiveness gap between OM-89 and placebo has decreased in more recent research.</p><p><strong>Conclusions: </strong>Although initial meta-analysis results indicated that OM-89 was effective in reducing UTI recurrence, meta-regression reveals a decline in its efficacy in more recent studies. This decreasing effectiveness over time suggests that OM-89 may no longer be a reliable option for preventing recurrent UTIs.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in efficacy and safety between HIF-PHIS and ESA/placebo in a sample of hemodialysis patients: a systematic review and meta-analysis.","authors":"Valeria Cernaro, Veronica Maressa, Guido Gembillo, Giulio Geraci, Chiara Casuscelli, Cristina Rossano, Domenico Santoro, Vincenzo Calabrese","doi":"10.23736/S2724-6051.25.06243-3","DOIUrl":"https://doi.org/10.23736/S2724-6051.25.06243-3","url":null,"abstract":"<p><strong>Introduction: </strong>Treatment of anemia is one of the main goals of supportive care in patients on hemodialysis. In this context, the use of therapy with hypoxia inducible factor inhibitors (HIF-PHI) represents a further promising resource. The main objective is to evaluate the difference in hemoglobin levels after treatment with HIF-PHI compared to placebo/ESA.</p><p><strong>Evidence acquisition: </strong>We performed a systematic search in PubMed, CINAHL, EMBASE, and Register of Controlled Trials (CENTRAL), looking for randomized controlled trials (RCTs). Eligible studies considered hemodialysis patients older than 18 years with the diagnosis of anemia treated with HIF-PHIs. Protocol was previously published on PROSPERO (CRD42024589848).</p><p><strong>Evidence synthesis: </strong>Among a total of 126 references, 32 citations were selected by screening of titles and abstracts, for full-text evaluation, and 14 articles referring were included in the review after the screening for full-text articles. Data on hemoglobin differences were reported by all studies and the pooled analysis involving 3890 patients (2267 in the experimental group and 1623 in the control group), network metanalysis did not show significant differences in Delta Hemoglobin among any HIF-PHIs types and ESA/placebo. Similarly, no significant differences were found comparing HIF-PHIs to ESA Splitting (11 studies, N.=3611). However, a significant difference was found comparing HIF-PHIs to Placebo (MD=1.48, 95%CI: 1.15/1.81, P<0.001). The experimental and control groups differed for gastrointestinal adverse events, whereas there were no differences for any other adverse events.</p><p><strong>Conclusions: </strong>The similar efficiency and safety between HIF-PHIs and ESA care could modify the usual clinical treatment of anemia in hemodialysis patients, and allow personalized therapy.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RAASi, MRA and FGF-23 in CKD progression: the usual suspects?","authors":"Giuseppe Cianciolo, Michele Provenzano, Lilio Hu, Simona Barbuto, Maria J Soler, Paola Ciceri, Mario Cozzolino, Gaetano LA Manna","doi":"10.23736/S2724-6051.25.06082-3","DOIUrl":"https://doi.org/10.23736/S2724-6051.25.06082-3","url":null,"abstract":"<p><p>Chronic kidney disease (CKD) affects almost 10% of the global population and is a significant health issue. The presence of CKD increases the risk of fatal and non-fatal cardiovascular events, overall mortality, and progression of renal damage leading to kidney failure. Inhibiting the renin-angiotensin-aldosterone system (RAAS) through angiotensin-converting enzyme inhibitor or angiotensin II receptor blockers reduces proteinuria and slows eGFR decline in CKD patients. Several factors can reduce the effect of inhibition RAAS, such as individual variations, drug intolerance, and adverse effects like hyperkalemia. Moreover, the aldosterone breakthrough phenomenon, where aldosterone levels rebound during RAAS therapy, limits treatment efficacy in reducing proteinuria and slowing the progression of CKD and is associated with poor cardiovascular and renal outcomes. Similarly, FGF23 attenuates RAAS blockade effectiveness through, in fact, enhancing the expression of angiotensin-converting enzyme 2 and reducing degradation of angiotensin I to angiotensin 1-9 and angiotensin II to angiotensin 1-7 inducing a reduced efficacy in controlling RAAS-mediated effects and an increase of cardiovascular risk and CKD progression. New therapeutic strategies to reduce the progression of CKD, such as SGLT-2 inhibitors, GLP-1 receptor agonists, and mineralocorticoid receptor antagonists (MRAs), are recommended in CKD patients to reduce the risk of progression and cardiovascular events. Furthermore, these therapies may reduce FGF-23 levels and regulate aldosterone breakthrough. This review aims to clarify the mechanisms underlying CKD progression, with a focus on aldosterone breakthrough, FGF-23, and activins, in order to identify new therapeutic approaches for better management of CKD and its complications.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145001942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy and safety of intravesical platelet-rich plasma injections into the bladder for the treatment of interstitial cystitis/bladder pain syndrome: a systematic review and meta-analysis.","authors":"Hai-Rui Li, Ting Wang, Si-Hong Shen, Liao Peng","doi":"10.23736/S2724-6051.25.06232-9","DOIUrl":"https://doi.org/10.23736/S2724-6051.25.06232-9","url":null,"abstract":"<p><strong>Introduction: </strong>Interstitial cystitis/bladder pain syndrome is a chronic bladder condition with a rising incidence that significantly impacts the lives of millions worldwide. The lack of understanding regarding the pathophysiology of this condition has resulted in a deficiency of effective treatment options. However, the development of regenerative medicine has brought platelet-rich plasma into our field of vision. Platelet-rich plasma may address unresolved inflammation in the interstitial cystitis/bladder pain syndrome bladder and facilitate the restoration of bladder and urethral barrier function through repeated injections, potentially reducing bladder pain. Our aim is to investigate the efficacy and safety of intravesical injection of platelet rich plasma in the treatment of interstitial cystitis/bladder pain syndrome.</p><p><strong>Evidence acquisition: </strong>A comprehensive search was conducted across PubMed, EMBASE, MEDLINE, Cochrane Library, and Web of Science databases for studies on platelet-rich plasma injection for the treatment of interstitial cystitis/bladder pain syndrome, with a search cutoff date of August 7, 2024.</p><p><strong>Evidence synthesis: </strong>A total of 11 studies with 391 participants were included. The combined statistics indicated that the baseline interstitial cystitis symptom index score was 11.20±4.60, the interstitial cystitis problem index score was 10.81±3.51, and the pain score was 4.37±3.14. The results showed that compared to pre-treatment, the interstitial cystitis symptom index score decreased by 3.56 (95% CI -4.39 to -2.72, P<0.00001), the interstitial cystitis problem index score decreased by 3.24 (95% CI -3.90 to -2.58, P<0.00001), and the pain score decreased by 1.84 (95% CI -2.19 to -1.48, P<0.00001). Additionally, the average proportion of patients with a global response assessment score of ≥2 after treatment was 48% (95% CI 0.37 to 0.58, P<0.00001). Furthermore, the overall incidence of adverse events among patients was 2.9%.</p><p><strong>Conclusions: </strong>Evidence-based statistical analysis results suggest that intravesical platelet-rich plasma treatment is effective and safe, potentially serving as a promising approach for managing interstitial cystitis/bladder pain syndrome.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145001961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of clinically insignificant residual fragments following endourological management of urolithiasis: a systematic review of complications and re-intervention rates.","authors":"Alberto Quarà, Letizia M Jannello, Alejandra Bravo-Balado, Stefano Moretto, Federico Zorzi, Ugo Gradilone, Hubert Werth, Mariela Corrales, Marie-Lou Letouche, Luigi Candela, Steeve Doizi, Frederic Panthier, Cristian Fiori, Olivier Traxer","doi":"10.23736/S2724-6051.25.06456-0","DOIUrl":"https://doi.org/10.23736/S2724-6051.25.06456-0","url":null,"abstract":"<p><strong>Introduction: </strong>Achieving stone-free status (SFS) is a key goal of endourological treatment, yet definitions of SFS and clinically insignificant residual fragments (CIRF) remain controversial. While CIRF is frequently defined as residual fragments ≤4 mm, there is no consensus on its clinical significance regarding complications and re-intervention needs. We evaluate the risk of complications and the need for re-intervention associated with the presence of CIRF following endourological treatment for urolithiasis.</p><p><strong>Evidence acquisition: </strong>PubMed/Medline, Scopus, Web Of Science, and Embase databases were searched for articles relating to SFS and CIRF definitions and outcomes, in February 2025, using keyword combinations: \"stone-free rate,\" \"residual fragments,\" \"clinically insignificant residual fragments,\" \"urinary calculi,\" \"urolithiasis,\" \"complications,\" and \"outcome\". Inclusion criteria were all studies with SFS/CIRF definition and complications associated with residual fragments following treatment (shock wave lithotripsy, ureteroscopy, or percutaneous nephrolithotomy).</p><p><strong>Evidence synthesis: </strong>Fifty-two studies met inclusion criteria. From the pooled analysis the probability of spontaneous expulsion of CIRF≤4 mm was 33% (95% CI: 12-50%; P<0.001), while regrowth occurred in 32% (95% CI: 23-40%; P<0.001). CIRF-related complications were observed in 27% (95% CI: 21-34%; P<0.001), and the re-intervention rate was 21% (95% CI: 16-26%; P<0.001). Within a variable mean follow-up ranging from 3 to 59 months. The risk of bias was moderate overall, with single-arm studies exhibiting the highest bias risk.</p><p><strong>Conclusions: </strong>Patients with CIRF≤4 mm should be monitored closely and informed about the non-neglectable likelihood of complications and of re-intervention. On the other hand, they have one probability out of three of spontaneous passage. Endourologist and patients should be aware of these outcomes to better plan the management, follow-up, and the \"insignificant\" nature of residual fragments. Hence, the aim of surgeries should be achieving the complete SFS, especially in high-risk stone former patients.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145001987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Robot-assisted modified Y-V plasty for bladder neck contracture: single-center comparative analysis.","authors":"Meng Liu, Ranxing Yang, Song Li, Xiaoyong Hu, Jihong Wang, Ying Wang, Lujie Song, Jianwen Huang, Qiang Fu","doi":"10.23736/S2724-6051.25.06283-4","DOIUrl":"https://doi.org/10.23736/S2724-6051.25.06283-4","url":null,"abstract":"<p><strong>Background: </strong>Bladder neck contracture (BNC) is common complication following surgery for benign prostate hyperplasia (BPH). Bladder neck reconstruction such as Y-V plasty may be considered for treatment of refractory BNC. This study aimed to compare the outcomes of robot-assisted modified Y-V plasty (RAMYV) and traditional Y-V plasty (RAYV) for refractory. Additionally, it seeks to establish a potential predictive system for postoperative patient-reported outcomes (PROs).</p><p><strong>Methods: </strong>We retrospectively analyzed clinical data of all patients with refractory BNC who underwent robot-assisted Y-V plasty from October 2022 and January 2024. Follow-up assessments were conducted at 1, 3 and 6 months.</p><p><strong>Results: </strong>Forty-eight patients with refractory BNC were included. 20 patients underwent RAYV, while 28 patients underwent RAMYV. All patients were followed for a period of six months. All patients had patent repairs and were voiding per urethra. Significant improvements were noted in the maximum urinary flow rate (Qmax), residual urine, and IPSS scores in both groups at 1, 3, and 6 months postoperatively, compared to the preoperative state. However, no statistically significant difference was found between the two groups at 1 month postoperatively. At 3 months postoperatively, the RAMYV group exhibited superior outcomes in IPSS and USS-PROM compared to the RAYV group, with statistically significant differences. At 6 months, the RAMYV group also exhibited superior outcomes in QoL and OAB-V8 compared to the RAYV group. Age and corresponding baseline scores on various scales are important predictors of lower urinary tract symptoms (LUTSs) after surgery. Preoperative scores on scales emphasizing flow assessment, such as the IPSS and USS PROM, carry significant weight, whereas age is the most influential factor in assessing storage function. This was a retrospective study, data bias was inevitable.</p><p><strong>Conclusions: </strong>YV plasty has been identified as an effective option for treating refractory BNC. Compared to RAYV, RAMYV appears to have better efficacy for patient outcomes in our six-month follow-up. Baseline scores related to age and preoperative symptom scores may serve as potential predictive factors for postoperative outcomes.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144796109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A drug-coated balloon treatment for urethral stricture: preliminary experience in an Italian real-life cohort.","authors":"Roberto Castellucci, Simone Morselli, Lorenzo Gatti, Giovanni Ferrari, Silvia Secco, Marcello Scarcia, Giuseppe M Ludovico, Lorenzo Spirito, Vincenzo Imperatore, Mirko Preto, Paolo Gontero, Francesco Persico, Paolo Fedelini, Francesco Trama, Giovanni Di Lauro, Danilo Dini, Ferdinando DE Marco, Luca Cindolo","doi":"10.23736/S2724-6051.25.06228-7","DOIUrl":"https://doi.org/10.23736/S2724-6051.25.06228-7","url":null,"abstract":"<p><strong>Background: </strong>Urethral stricture is an abnormal narrowing of the urethra and occurs in anterior urethra for 92% of cases. Although open surgery is considered the gold standard for this type of disease, endoscopic procedures are the most commonly used. The Optilume^® Drug Coated Balloon (DCB) (Urotronic, Inc., Plymouth, MN, USA) is the first DCB intended for the treatment of male urethral strictures. Here we report the results of a multicenter Italian real-life study.</p><p><strong>Methods: </strong>We collected data from nine Italian centers. Patients with urethral strictures or bladder neck stricture were treated with the Optilume^© DCB. We evaluated variation in IPSS, QoL and IIEF5 score, QMax, PVR, and freedom from repeat intervention.</p><p><strong>Results: </strong>Overall, 130 subjects were treated; median follow-up was six months. Mean age and prostate volume were 64 and 45 mL. Total median operative time was 15 minutes whereas the median time of Optilume application was 7 minutes. IPSS and QoL changed from a mean of 24 and 4 points at baseline to 10 and 1 points respectively at the last follow-up (P<0.001). We have also recorded a significant improvement in Qmax and PVR from 8 mL/s and 100 mL at baseline to 17.8 mL/s and 0 mL at the last follow-up (P<0.001). Intra and post operative not serious complications occurred in 3 and 10 patients, respectively. Six patients underwent reoperation during follow-up.</p><p><strong>Conclusions: </strong>In our experience, the Optilume^© represents a valid option in the management of patients with urethral stricture, with or without previous surgery.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144796107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Agreement between artificial intelligence, experts, and the European Association of Urology Guidelines: insights from a study on the management of benign prostatic hyperplasia.","authors":"Francesca Vedovo, Paolo Capogrosso, Serena Maruccia, Simonetta Fracalanza, Fabrizio Dal Moro, Giovanni Liguori","doi":"10.23736/S2724-6051.25.06609-1","DOIUrl":"https://doi.org/10.23736/S2724-6051.25.06609-1","url":null,"abstract":"","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144796108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}